Rochigneux P, Bertucci A, Loir E, Mattei A, Robert D, Dassa M
Front Immunol. 2025; 16:1496427.
PMID: 39995675
PMC: 11847840.
DOI: 10.3389/fimmu.2025.1496427.
Wu K, Yakobi Y, Gueorguieva D, Mazerolle E
Biomedicines. 2024; 12(11).
PMID: 39595113
PMC: 11592388.
DOI: 10.3390/biomedicines12112547.
Malvaso A, Giglio P, Diamanti L, Gastaldi M, Vegezzi E, Pace A
Brain Sci. 2024; 14(8).
PMID: 39199458
PMC: 11352216.
DOI: 10.3390/brainsci14080764.
Neto Silva I, Kharat A, Marzano F, Marchi E, Duarte J, Bendjelid K
Chest. 2024; 165(6):e177-e185.
PMID: 38852975
PMC: 11177100.
DOI: 10.1016/j.chest.2024.01.002.
Racine J, Bachman J, Zhang J, Misherghi A, Khadour R, Kaisar S
J Immunol. 2024; 212(8):1287-1306.
PMID: 38426910
PMC: 10984778.
DOI: 10.4049/jimmunol.2300841.
Pembrolizumab-induced Myopathy with Anti-striated Muscle Antibodies Successfully Treated by Plasma Exchange.
Takahashi S, Okabayashi K, Soejima I, Oniki A, Ishihara S, Tomimitsu H
Intern Med. 2023; 62(23):3525-3530.
PMID: 38044116
PMC: 10749821.
DOI: 10.2169/internalmedicine.1222-22.
Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications.
Banerjee A, Aluganti Narasimhulu C, Singla D
Am J Physiol Heart Circ Physiol. 2023; 325(4):H751-H767.
PMID: 37594487
PMC: 10659324.
DOI: 10.1152/ajpheart.00378.2023.
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.
Martens A, Schauwvlieghe P, Madoe A, Casteels I, Aspeslagh S
J Ophthalmic Inflamm Infect. 2023; 13(1):5.
PMID: 36811715
PMC: 9947214.
DOI: 10.1186/s12348-022-00321-2.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S, Gelsomino F, Rinaldi R, Muccioli L, Comito F, Di Federico A
J Neurol. 2023; 270(6):2975-2986.
PMID: 36800019
PMC: 10188572.
DOI: 10.1007/s00415-023-11625-1.
Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.
Wang S, Peng D, Zhu H, Min W, Xue M, Wu R
Front Oncol. 2022; 12:1053370.
PMID: 36568231
PMC: 9773380.
DOI: 10.3389/fonc.2022.1053370.
Multisystem immune-related adverse events due to toripalimab: Two cases-based review.
Chen Y, Chen Y, Xie J, Liu D, Hong X
Front Cardiovasc Med. 2022; 9:1036603.
PMID: 36505392
PMC: 9732722.
DOI: 10.3389/fcvm.2022.1036603.
The radiological appearances of lung cancer treated with immunotherapy.
Milanese G, Mazzaschi G, Ledda R, Balbi M, Lamorte S, Caminiti C
Br J Radiol. 2022; 96(1144):20210270.
PMID: 36367539
PMC: 10078868.
DOI: 10.1259/bjr.20210270.
Neurology of cancer immunotherapy.
De Grado A, Cencini F, Priori A
Neurol Sci. 2022; 44(1):137-148.
PMID: 36112276
PMC: 9816208.
DOI: 10.1007/s10072-022-06297-0.
Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.
Harish Bindiganavile S, Bhat N, Lee A, Gombos D, Al-Zubidi N
J Immunother Precis Oncol. 2022; 4(1):6-15.
PMID: 35664825
PMC: 9161666.
DOI: 10.36401/JIPO-20-21.
Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N, Maeda A, Takase-Minegishi K, Kirino Y, Sugiyama Y, Namkoong H
Front Immunol. 2021; 12:803410.
PMID: 34938300
PMC: 8686164.
DOI: 10.3389/fimmu.2021.803410.
Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
Rapoport B, Shannon V, Cooksley T, Johnson D, Anderson L, Blidner A
Front Pharmacol. 2021; 12:743582.
PMID: 34675810
PMC: 8523897.
DOI: 10.3389/fphar.2021.743582.
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M, Kitano S, Suzuki S
Cancer Immunol Immunother. 2021; 71(4):769-775.
PMID: 34515815
PMC: 10992020.
DOI: 10.1007/s00262-021-03053-9.
Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies.
Sugiyama A, Onishi Y, Ito K, Shibuya K, Nakamura K, Oda F
Intern Med. 2021; 60(16):2671-2675.
PMID: 33642484
PMC: 8429292.
DOI: 10.2169/internalmedicine.6834-20.
Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.
Yeung S, Qdaisat A, Chaftari P, Lipe D, Merlin J, Rajha E
J Am Coll Emerg Physicians Open. 2021; 1(6):1637-1659.
PMID: 33392573
PMC: 7771833.
DOI: 10.1002/emp2.12209.
Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z, Zhang C, Zhou L, Dong P, Shi L
Curr Neuropharmacol. 2020; 19(8):1246-1263.
PMID: 33380303
PMC: 8719293.
DOI: 10.2174/1570159X19666201230151224.
